Novel MRI and fluorescent probes responsive to the Factor XIII transglutaminase activity

Lorenzo Tei, Galit Mazooz, Yael Shellef, Reut Avni, Katrien Vandoorne, Alessandro Barge, Vyacheslav Kalchenko, Mark W. Dewhirst, Linda Chaabane, Luigi Miragoli, Dario Longo, Michal Neeman, Silvio Aime

Research output: Contribution to journalArticlepeer-review


Transglutaminases, including factor XIII and tissue transglutaminase, participate in multiple extracellular processes associated with remodeling of the extracellular matrix during wound repair, blood clotting, tumor progression and fibrosis of ischemic injuries. The aim of this work was to evaluate a novel substrate analog for transglutaminase optimized by molecular modeling calculations (DCCP16), which can serve for molecular imaging of transglutaminase activity by magnetic resonance imaging and by near-infrared imaging. Experimental data showed covalent binding of Gd-DCCP16 and DCCP16-IRIS Blue to human clots, to basement membrane components and to casein in purified systems as well as in three-dimensional multicellular spheroids. In vivo, DCCP16 showed enhancement with a prolonged retention in clots and tumors, demonstrating the ability to detect both factor XIII and tissue transglutaminase mediated covalent binding of the contrast material.

Original languageEnglish
Pages (from-to)213-222
Number of pages10
JournalContrast Media and Molecular Imaging
Issue number4
Publication statusPublished - Jul 2010


  • Blood clotting
  • Magnetic resonance imaging
  • Molecular imaging
  • Near infrared imaging
  • Responsive contract agents
  • Transglutaminase activity
  • Tumor imaging

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging


Dive into the research topics of 'Novel MRI and fluorescent probes responsive to the Factor XIII transglutaminase activity'. Together they form a unique fingerprint.

Cite this